Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2109 and Toripalimab in Solid Tumors
NCT07680582Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABO2109 in solid tumor, sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
ABO2109
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07680582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680582.